14 September 2016 - Joseph Damond, Senior Vice President, International Affairs at the Biotechnology Innovation Organization, has released a statement in response to the new United Nations High Level Panel on Access to Medicines Report.

“While we are still reviewing the full report released today by the UN High Level Panel on Access to Medicines, it is clear from an initial review that this report ignores the real issues that impact or delay delivery of innovative treatments and cures throughout the developing world, while focusing on policy recommendations in the one area – intellectual property – that would actually undermine ongoing research and development by hundreds of companies, universities and researchers.

“The Panel’s report fails to recognize the complexity around biopharma research and development and the many efforts already taking place to advance access to care. Without the innovation incentivized through strong intellectual property protections the costly and challenging work will simply not take place.

Read BIO press release